271 related articles for article (PubMed ID: 15023365)
1. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets.
Vieth M; Higgs RE; Robertson DH; Shapiro M; Gragg EA; Hemmerle H
Biochim Biophys Acta; 2004 Mar; 1697(1-2):243-57. PubMed ID: 15023365
[TBL] [Abstract][Full Text] [Related]
2. Chemical genetic approaches to kinase drug discovery.
Gallion SL; Qian D
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):638-45. PubMed ID: 16159026
[TBL] [Abstract][Full Text] [Related]
3. Chemical kinomics: a powerful strategy for target deconvolution.
Kim DH; Sim T
BMB Rep; 2010 Nov; 43(11):711-9. PubMed ID: 21110913
[TBL] [Abstract][Full Text] [Related]
4. Interrogating the druggable genome with structural informatics.
Hambly K; Danzer J; Muskal S; Debe DA
Mol Divers; 2006 Aug; 10(3):273-81. PubMed ID: 17031532
[TBL] [Abstract][Full Text] [Related]
5. Kinomics: characterizing the therapeutically validated kinase space.
Vieth M; Sutherland JJ; Robertson DH; Campbell RM
Drug Discov Today; 2005 Jun; 10(12):839-46. PubMed ID: 15970266
[TBL] [Abstract][Full Text] [Related]
6. Chemogenomics: structuring the drug discovery process to gene families.
Harris CJ; Stevens AP
Drug Discov Today; 2006 Oct; 11(19-20):880-8. PubMed ID: 16997137
[TBL] [Abstract][Full Text] [Related]
7. The design of drug candidate molecules as selective inhibitors of therapeutically relevant protein kinases.
Fischer PM
Curr Med Chem; 2004 Jun; 11(12):1563-83. PubMed ID: 15180564
[TBL] [Abstract][Full Text] [Related]
8. Affinity purification of proteins binding to kinase inhibitors immobilized on self-assembling monolayers.
Bantscheff M; Hobson S; Kuster B
Methods Mol Biol; 2012; 795():149-60. PubMed ID: 21960221
[TBL] [Abstract][Full Text] [Related]
9. Selectivity of kinase inhibitor fragments.
Bamborough P; Brown MJ; Christopher JA; Chung CW; Mellor GW
J Med Chem; 2011 Jul; 54(14):5131-43. PubMed ID: 21699136
[TBL] [Abstract][Full Text] [Related]
10. FDA-approved small-molecule kinase inhibitors.
Wu P; Nielsen TE; Clausen MH
Trends Pharmacol Sci; 2015 Jul; 36(7):422-39. PubMed ID: 25975227
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
12. Predicting kinase selectivity profiles using Free-Wilson QSAR analysis.
Sciabola S; Stanton RV; Wittkopp S; Wildman S; Moshinsky D; Potluri S; Xi H
J Chem Inf Model; 2008 Sep; 48(9):1851-67. PubMed ID: 18717582
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
14. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis.
Huang D; Zhou T; Lafleur K; Nevado C; Caflisch A
Bioinformatics; 2010 Jan; 26(2):198-204. PubMed ID: 19942586
[TBL] [Abstract][Full Text] [Related]
15. BioGPS: navigating biological space to predict polypharmacology, off-targeting, and selectivity.
Siragusa L; Cross S; Baroni M; Goracci L; Cruciani G
Proteins; 2015 Mar; 83(3):517-32. PubMed ID: 25556939
[TBL] [Abstract][Full Text] [Related]
16. Development of Kinase-Centric Drugs: A Computational Perspective.
Pratap Reddy Gajulapalli V
ChemMedChem; 2023 Oct; 18(19):e202200693. PubMed ID: 37442809
[TBL] [Abstract][Full Text] [Related]
17. Kinomics.
Gomase VS; Tagore S
Curr Drug Metab; 2008 Mar; 9(3):255-8. PubMed ID: 18336231
[TBL] [Abstract][Full Text] [Related]
18. Exploring the scaffold universe of kinase inhibitors.
Hu Y; Bajorath J
J Med Chem; 2015 Jan; 58(1):315-32. PubMed ID: 25192260
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase inhibitors: insights into drug design from structure.
Noble ME; Endicott JA; Johnson LN
Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
